Swedish Orphan Biovitrum AB (publ) (OM:SOBI) entered into a definitive agreement to acquire Arthrosi Therapeutics, Inc. for $1.5 billion on December 13, 2025. Under the terms of the agreement, Sobi will pay $950 million upfront in cash to acquire Arthrosi, together with up to $550 million in cash in clinical, regulatory and sales milestones. Sobi plans to fund the upfront payment mainly through debt in the form of existing credit facilities and a new credit facility provided by Handelsbanken and Danske Bank.
The transaction is subject to the satisfaction of customary closing conditions and is expected to close in H1 2026. The acquisition is expected to be highly accretive to Sobi?s mid- to long-term growth and margin trajectory.
Barclays Bank PLC act as financial advisor, McDermott Will & Schulte LLP act as legal advisor for Swedish Orphan Biovitrum AB. Wilson Sonsini Goodrich & Rosati, P.C. acted as legal advisor to Arthrosi Therapeutics, Inc.
Wenseng ?Wendy? Pan, Shoaib Ghias, David R. Chen, Susan Lee, Jacqueline Klosek, April Sun, Nina Ngo, Malhar Naik, Eric Graffeo, Justin C. Pierce, Daniel S. Karelitz, Arman Oruc, Brady Cummins, Kevin Walsh, Robert D. Carroll and Heath R. Ingram of Goodwin Procter LLP served as legal advisor to Arthrosi Therapeutics.
Swedish Orphan Biovitrum AB (publ) (OM:SOBI) completed the acquisition of Arthrosi Therapeutics, Inc. on February 9, 2026.
Swedish Orphan Biovitrum AB (publ) is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
